Benaroya Research Institute
@benaroyaresearch.bsky.social
Working toward our vision of a healthy immune system for everyone.
Read more: bri-news.short.gy/UdQhHg
September 18, 2025 at 4:55 PM
Read more: bri-news.short.gy/UdQhHg
This project was also supported by collaborations with the laboratories of Dr. Ryan Tewhey at the Jackson Laboratory in Bar Harbor, Maine, Dr. Carl de Boer at the University of British Columbia, Dr. Michael Guo at the University of Pennsylvania, and Dr. Jay Shendure at the University of Washington.
September 18, 2025 at 4:55 PM
This project was also supported by collaborations with the laboratories of Dr. Ryan Tewhey at the Jackson Laboratory in Bar Harbor, Maine, Dr. Carl de Boer at the University of British Columbia, Dr. Michael Guo at the University of Pennsylvania, and Dr. Jay Shendure at the University of Washington.
“These primary CD4 T cell emVars serve as a great jumping-off point for in-depth functional studies to identify genes that cause multiple autoimmune diseases. This brings us a step closer to understanding the mechanisms underlying autoimmune diseases and finding therapeutic targets,” said Dr. Ray.
September 18, 2025 at 4:55 PM
“These primary CD4 T cell emVars serve as a great jumping-off point for in-depth functional studies to identify genes that cause multiple autoimmune diseases. This brings us a step closer to understanding the mechanisms underlying autoimmune diseases and finding therapeutic targets,” said Dr. Ray.
This research not only highlights new pathways involved in autoimmune disease but also identifies potential therapeutic targets for diseases such as multiple sclerosis, rheumatoid arthritis, type 1 diabetes, and inflammatory bowel disease.
September 18, 2025 at 4:55 PM
This research not only highlights new pathways involved in autoimmune disease but also identifies potential therapeutic targets for diseases such as multiple sclerosis, rheumatoid arthritis, type 1 diabetes, and inflammatory bowel disease.
The researchers identified 545 specific expression-modulating variants (emVars) that likely affect how genes in T cells behave. Many of these variants were found to influence how T cells grow and respond, suggesting they play a key role in autoimmunity.
September 18, 2025 at 4:55 PM
The researchers identified 545 specific expression-modulating variants (emVars) that likely affect how genes in T cells behave. Many of these variants were found to influence how T cells grow and respond, suggesting they play a key role in autoimmunity.
Unlike past studies that used cancer cell lines (which don’t always reflect real human immune cells), this study used T cells directly from human donors, providing a more accurate view.
September 18, 2025 at 4:55 PM
Unlike past studies that used cancer cell lines (which don’t always reflect real human immune cells), this study used T cells directly from human donors, providing a more accurate view.
Led by BRI’s John Ray, PhD, (@jraylab.bsky.social) researchers tested more than 18,000 genetic variants with a possible link to autoimmunity.
September 18, 2025 at 4:55 PM
Led by BRI’s John Ray, PhD, (@jraylab.bsky.social) researchers tested more than 18,000 genetic variants with a possible link to autoimmunity.
Reposted by Benaroya Research Institute
This was made possible because of a partnership with @benaroyaresearch.bsky.social and Children's Hospital of Philadelphia.
alleninstitute.org/news/allen-i...
alleninstitute.org/news/allen-i...
Allen Institute for Immunology unveils landmark Human Immune Health Atlas
Comprehensive dataset maps the landscape of healthy immune cells across the human lifespan
alleninstitute.org
September 15, 2025 at 8:19 PM
This was made possible because of a partnership with @benaroyaresearch.bsky.social and Children's Hospital of Philadelphia.
alleninstitute.org/news/allen-i...
alleninstitute.org/news/allen-i...
Learn more from @gohealio.bsky.social:
Inflammatory drivers of asthma exacerbations identified in children receiving mepolizumab
Among children with eosinophilic asthma receiving mepolizumab who had an exacerbation during an acute respiratory illness, three axes of inflammation were found, according to results published in JAMA Pediatrics.“Better understanding of the parts of the immune response in the lung which promotes asthma attacks can lead to more personalized treatments in the long run and lead to a push for
bri-news.short.gy
September 5, 2025 at 10:18 PM
Learn more from @gohealio.bsky.social:
Learn more from Fierce Biotech:
New foundation from Microsoft co-founder reveals inaugural research grants, pledges $500M funding
A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant recipi | A new foundation from the estate of late Microsoft co-founder Paul Alle...
bri-news.short.gy
August 29, 2025 at 6:24 PM
Learn more from Fierce Biotech:
Learn more from @forbes.com:
InnovationRx: Paul Allen Estate Launches $500 Million Research Fund
In this week’s edition of InnovationRx, we look at whether Congress will extend Obamacare subsidies, the latest data on Lilly’s obesity pill and more.
bri-news.short.gy
August 28, 2025 at 10:03 PM
Learn more from @forbes.com:
Learn more from Genetic Engineering and Biotechnology News:
New Fund for Science and Technology Announces Inaugural Grants
The foundation is launching with an initial slate of grants to local scientific centers of excellence in Seattle.
bri-news.short.gy
August 28, 2025 at 9:53 PM
Learn more from Genetic Engineering and Biotechnology News:
Learn more from the Puget Sound Business Journal:
bri-news.short.gy
August 28, 2025 at 9:34 PM
Learn more from the Puget Sound Business Journal:
Learn more from @seattletimes.com:
New $500M push to bring Microsoft co-founder Paul Allen’s ‘vision to bear’
A new Paul Allen estate-backed foundation pledged $500 million to scientific efforts over the next four years.
bri-news.short.gy
August 28, 2025 at 9:13 PM
Learn more from @seattletimes.com:
Learn more from @geekwire.com:
Microsoft co-founder Paul Allen’s final act: New $3.1B foundation bets big on science and tech
Microsoft co-founder Paul Allen’s estate launches a $3.1B Fund for Science and Technology to back bold research in bioscience, AI, and climate.
www.geekwire.com
August 28, 2025 at 8:30 PM
Learn more from @geekwire.com:
(8/8): The CAUSE Network is supported by the National Institutes of Health — National Institute of Allergy and Infectious Diseases.
July 15, 2025 at 3:23 PM
(8/8): The CAUSE Network is supported by the National Institutes of Health — National Institute of Allergy and Infectious Diseases.
(7/8):
✍️ Editorial from @gustavonino.bsky.social; Jose L. Gomez, MD, MS; and @mgutie.bsky.social: bri-news.short.gy/ritZSs
✍️ Editorial from @pedsleeppulm.bsky.social and Jason S. Debley, MD, MPH: bri-news.short.gy/0AA14y
✍️ Editorial from @gustavonino.bsky.social; Jose L. Gomez, MD, MS; and @mgutie.bsky.social: bri-news.short.gy/ritZSs
✍️ Editorial from @pedsleeppulm.bsky.social and Jason S. Debley, MD, MPH: bri-news.short.gy/0AA14y
July 15, 2025 at 3:23 PM
(7/8):
✍️ Editorial from @gustavonino.bsky.social; Jose L. Gomez, MD, MS; and @mgutie.bsky.social: bri-news.short.gy/ritZSs
✍️ Editorial from @pedsleeppulm.bsky.social and Jason S. Debley, MD, MPH: bri-news.short.gy/0AA14y
✍️ Editorial from @gustavonino.bsky.social; Jose L. Gomez, MD, MS; and @mgutie.bsky.social: bri-news.short.gy/ritZSs
✍️ Editorial from @pedsleeppulm.bsky.social and Jason S. Debley, MD, MPH: bri-news.short.gy/0AA14y
July 15, 2025 at 3:23 PM
(5/8): This research not only explains why some children don’t fully respond to mepolizumab — it also identifies new, targetable disease pathways that could shape more personalized treatments.
July 15, 2025 at 3:23 PM
(5/8): This research not only explains why some children don’t fully respond to mepolizumab — it also identifies new, targetable disease pathways that could shape more personalized treatments.
(4/8): “These results tell us that asthma in urban children isn’t a disease driven by a single pathway,” says Dr. Altman. “Even when we suppress one part of the immune system, others can take over and continue to drive asthma attacks.”
July 15, 2025 at 3:23 PM
(4/8): “These results tell us that asthma in urban children isn’t a disease driven by a single pathway,” says Dr. Altman. “Even when we suppress one part of the immune system, others can take over and continue to drive asthma attacks.”
(3/8): The research team found that while mepolizumab effectively suppresses type 2 inflammation, children who continued to experience asthma attacks had disease involving other immune pathways not blocked by the therapy.
July 15, 2025 at 3:23 PM
(3/8): The research team found that while mepolizumab effectively suppresses type 2 inflammation, children who continued to experience asthma attacks had disease involving other immune pathways not blocked by the therapy.
(2/8): Led by BRI’s Matthew C. Altman, MD, MPhil, and Daniel J. Jackson of @uwmadison.bsky.social, researchers from the CAUSE Network analyzed data from the MUPPITS-2 clinical trial to learn why some children still have asthma attacks despite treatment with mepolizumab.
July 15, 2025 at 3:23 PM
(2/8): Led by BRI’s Matthew C. Altman, MD, MPhil, and Daniel J. Jackson of @uwmadison.bsky.social, researchers from the CAUSE Network analyzed data from the MUPPITS-2 clinical trial to learn why some children still have asthma attacks despite treatment with mepolizumab.